Baldwin Wealth Partners LLC MA Trims Stake in Johnson & Johnson (NYSE:JNJ)

Baldwin Wealth Partners LLC MA decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.5% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 84,337 shares of the company’s stock after selling 5,823 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Johnson & Johnson were worth $12,197,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Quarry LP purchased a new position in Johnson & Johnson during the second quarter valued at $49,000. Ashburton Jersey Ltd purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth about $8,771,000. Mattson Financial Services LLC bought a new position in Johnson & Johnson in the 2nd quarter worth about $3,407,000. First Financial Bank Trust Division increased its stake in Johnson & Johnson by 1.3% during the 3rd quarter. First Financial Bank Trust Division now owns 62,803 shares of the company’s stock valued at $10,178,000 after purchasing an additional 779 shares in the last quarter. Finally, Davis Capital Management lifted its stake in shares of Johnson & Johnson by 4.4% in the third quarter. Davis Capital Management now owns 10,432 shares of the company’s stock worth $1,691,000 after buying an additional 441 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on JNJ shares. Guggenheim boosted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Wolfe Research initiated coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company decreased their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $152.78 on Friday. The business has a 50-day moving average price of $147.73 and a 200-day moving average price of $156.10. The firm has a market cap of $367.82 billion, a price-to-earnings ratio of 22.97, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 10.56 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.25%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.